Shen 4-marker miRNA panel for lung cancer
We initially validated expressions of a set of miRNAs in paired lung tumor tissues and plasma specimens from 28 stage I NSCLC patients by real-time quantitative reverse transcription PCR, and then evaluated diagnostic value of the plasma miRNAs in a cohort of 58 NSCLC patients and 29 healthy individuals. The altered miRNA expressions were reproducibly confirmed in the tumor tissues. The miRNAs were stably present and reliably measurable in plasma. A logistic regression model with the best prediction was defined on the basis of the four genes (miRNA-21, -126, -210, and 486-5p), yielding 86.22% sensitivity and 96.55% specificity in distinguishing NSCLC patients from the healthy controls. (Lab Invest. 2011 Apr;91(4):579-87, PMID: 21116241)
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
We previously identified 12 microRNAs (miRNAs) the aberrant expressions of which in primary lung tumors are associated with early-stage NSCLC. Of the 12 miRNAs, five displayed significant concordance of the expression levels in plasma and the corresponding tumor tissues. A logistic regression model with the best prediction was defined on the basis of the four of these genes (miRNA-21, -126, -210, and 486-5p).
No associated resources found.